Global /Japan /Healthcare /Biotechnology /206A

PRISM BioLab Co.,LTD

206A

• TSE: 206A • Delayed

175JPY -4.9%

1.09 USD

As of 7 June 2026, PRISM BioLab Co.,LTD has a market cap of $42.47M USD, ranking #31731 globally and #2975 in Japan. It ranks #2867 in the Healthcare sector, and #555 in the Biotechnology industry.

Global Rank

31731

Country Rank

2975

Sector Rank

2867

Industry Rank

555

Key Stats

Market Cap

$42.47MUSD

6.8B JPY

Enterprise Value

$24.82MUSD

3.97B JPY

Revenue (TTM)

$4.28MUSD

684.61M JPY

Net Income (TTM)

-$5.8MUSD

-927.75M JPY

Profit Margin

-136%

PS Ratio

9.9

PB Ratio

2.8

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Biotechnology

CEO

Dai Takehara open_in_new

Founded

2006

Website

prismbiolab.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.9%	-3.7%	-4.2%	1.7%	12%	18%	-29%	-70%	-70%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	206A 株式会社 PRISM BioLab ISIN: JP3833190006 Shares Out.: Shares Outstanding: 36.964M¹ Shares Float: 17.317M² TV: TradingView: TSE: 206A SA: Stock Analysis: TYO: 206A YF: Yahoo Finance: 206A.T GF: Google Finance: TYO: 206A BA: Barron's: 206A MS: Morningstar: XTKS: 206A	175 JPY	TV: TradingView: TSE: 206A SA: Stock Analysis: TYO: 206A YF: Yahoo Finance: 206A.T GF: Google Finance: TYO: 206A BA: Barron's: 206A MS: Morningstar: XTKS: 206A

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About PRISM BioLab Co.,LTD

PRISM BioLab Co.,LTD engages in the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has a strategic collaboration with Receptor.AI Inc. for the development of an AI-integrated drug discovery platform. The company was founded in 2006 and is based in Fujisawa, treating Japan.

Similar Companies

Industry: Biotechnology (Japan)

Name	Market Cap (USD) diff.	PE	Country
GNI Group Ltd. TSE: 2160	$1.02B 162.8B JPY 2K%	-	Japan
PeptiDream Inc. TSE: 4587	$929.38M 148.73B JPY 2K%	-	Japan
Oncolys BioPharma Inc. TSE: 4588	$526.3M 84.22B JPY 1K%	-	Japan
Cuorips Inc. TSE: 4894	$349.85M 55.99B JPY 724%	-	Japan
Innovacell Inc. TSE: 504A	$169.94M 27.19B JPY 300%	-	Japan
Stella Pharma Corp. TSE: 4888	$113.62M 18.18B JPY 168%	-	Japan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 429K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 376K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 113K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 105K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 101K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 100K%	37.2	Switzerland

chevron_leftBack